The DOI matches its Crossref record; 159 of the 184 references it cites were found in a registry or an index, and 18 are not checked yet; 108 of the 180 sources its claims cite were checked for support.
Current Concepts in Probiotic Safety and Efficacy
Open accessAbstract
This review summarizes current knowledge on the efficacy and safety of probiotics, analyzes limitations in clinical safety reporting, and compares regulatory frameworks governing the use of probiotics as dietary supplements, medicinal products, and live biotherapeutics. Particular attention is given to new genomic and computational approaches to safety assessment. Overall, the review emphasizes the need for coordinated regulation, rigorous clinical evidence, and integrated, modern safety assessment strategies to support the responsible expansion of probiotic use.
Verified 2026-10-09 · 18 references not checked yet
Overview
CoChat Summary
## TL;DR
This review argues that probiotics are generally safe for healthy people, but their safety and efficacy are highly strain-, dose-, host-, and context-dependent, with rare but serious harms reported in vulnerable groups. It also emphasizes that next-generation probiotics need stronger genomic, phenotypic, clinical, and regulatory scrutiny, alongside harmonized standards.
## Key findings
- Probiotics are “generally safe” for healthy individuals, but rare clinically significant adverse events have been reported, including bacteremia and endocarditis, especially in people with implanted devices, impaired barrier function, severe comorbidities, immunodeficiency, or critical illness.
- The review states that adverse-event data are incomplete: it says the true incidence of probiotic-associated infections is unknown because of lack of systematic reporting and weak post-market harm detection, and that most side effects are described in individual case reports rather than randomized trials.
- Clinical safety evidence is heterogeneous: the text notes 2 randomized controlled trials, 7 systematic reviews (including case reports), and 1 case report among the cited safety literature, with populations spanning healthy adults, mixed groups, and high-risk patients.
- A cited analysis of 622 randomized clinical studies found no statistically significant increase in relative risk for total adverse events, including serious ones, with short-term probiotic use versus controls; another report described 93 serious infections with a 15% mortality rate, including fungemia (37.6%), sepsis (31.2%), bacteremia (20.4%), endocarditis, and abscesses.
- Safety assessment should be strain-specific and multi-level: strain identification, phenotypic antimicrobial susceptibility testing, whole-genome sequencing, in vitro assays, preclinical models, and clinical trials/meta-analyses all contribute, while AI/computational tools are described as supportive but still preliminary/experimental.
## Methods
- Narrative review of current concepts in probiotic safety, efficacy, regulation, and computational assessment; the abstract states it “summarizes current knowledge,” analyzes limitations in clinical safety reporting, and compares regulatory frameworks.
- The paper draws on published literature and regulatory documents, including cited safety studies and frameworks from EFSA, FDA, FAO/WHO, and Russian regulations.
- Main analysis is qualitative synthesis: it contrasts traditional probiotics, next-generation probiotics, and live biotherapeutic products; reviews safety risks, reporting limitations, and genomic/computational screening approaches.
## Limitations
- The paper states that clinical safety reporting is limited by “lack of systematic reporting on adverse effects” and ineffective post-registration harm detection.
- It also states that many studies are heterogeneous in design, endpoints, strain identification, dosing, formulations, and populations, which reduces comparability and reproducibility.
- Evidence for AI/computational approaches is still preliminary and many predictions require external validation and biological confirmation; this is stated in the paper.
- Evident from the text: the review relies on narrative synthesis rather than a single new experimental dataset, so its conclusions depend on the quality and consistency of the underlying literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
66 Valid · 7 Not valid · 42 Not checked · 71 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Recent studies have linked probiotic-induced cytokine production, such as interleukins IL-1β, IL-6, tumor necrosis factor TNF-α, and interferons, to excessive immune reactions that can lead to autoimmune disorders or inflammation [12,86].”
§ Current Concepts in Probiotic Safety and Efficacy > 3. Safety, Toxicity and Other Risks Associated with Probiotics
What the sources say
- Disputedcites [12] Pyo Y. Kwon K.H. Jung Y.J. Probiotic functions in fermented foods: Anti-viral, immunomodulatory, and anti-cancer benefits Foods 2024 13 2386 10.3390/foods13152386 39123577 PMC11311591 sourceExperimental — accuracy not yet measured
Section 3, “Mechanisms of Health Benefits of Fermented Foods” (page unavailable), says probiotics downregulate pro-inflammatory cytokines and prevent inflammatory events—the opposite of the claimed link to excessive inflammation. Sections 4 and 5 likewise describe reductions in inflammatory factors, including TNF-α, interferon-γ, and IL-1β. The cited paper does not link probiotic-induced cytokine production to autoimmune disorders. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [86] Ashraf R. Vasiljevic T. Day S.L. Smith S.C. Donkor O.N. Lactic acid bacteria and probiotic organisms induce different cytokine profile and regulatory T cells mechanisms J. Funct. Foods 2014 6 395 409 10.1016/j.jff.2013.11.006 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Although probiotics are generally safe for healthy individuals, rare but clinically significant infectious events, including bacteremia and endocarditis, have been reported, particularly in patients with implanted devices, impaired barrier function, or severe comorbidities [63].”
§ Current Concepts in Probiotic Safety and Efficacy > 3. Safety, Toxicity and Other Risks Associated with Probiotics
What the sources say
- Supportedcites [63] Doron S. Snydman D.R. Risk and safety of probiotics Clin. Infect. Dis. 2015 60 S129 S134 10.1093/cid/civ085 25922398 PMC4490230 source
The Systemic Infections discussion (indexed as Abstract; page unavailable) reports probiotic-associated bacteremia and endocarditis, including bacteremia in patients with central venous catheters. Table 2 (also indexed as Abstract) identifies valve replacements, bowel-wall translocation risks, and immunosuppression as potential risk factors; the cited case reports include patients with substantial comorbidities. (LLM, conf=0.89)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In contrast, studies involving mixed or high-risk populations, including patients receiving parenteral nutrition, those in intensive care, or patients with cancer, describe rare but serious adverse events in detail [73].”
§ Current Concepts in Probiotic Safety and Efficacy > 3. Safety, Toxicity and Other Risks Associated with Probiotics
What the sources say
- Supportedcites [73] Whelan K. Myers C.E. Safety of probiotics in patients receiving nutritional support: A systematic review of case reports, randomized controlled trials, and nonrandomized trials Am. J. Clin. Nutr. 2010 91 687 703 10.3945/ajcn.2009.28759 20089732 source
The Discussion reports 32 probiotic infections among patients receiving enteral or parenteral nutritional support, against 4,131 probiotic recipients in clinical trials. The case-report findings describe bacteremia and fungemia, including deaths; the paper also discusses ICU patients and cites a case of fungemia in a patient with head and neck cancer. These findings support the characterization of rare but serious adverse events in mixed or high-risk groups. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additional risks arise from strain-specific metabolic activity, such as the production of D-lactate or biogenic amines, which justifies targeted biochemical screening during the development phase [64,65].”
§ Current Concepts in Probiotic Safety and Efficacy > 3. Safety, Toxicity and Other Risks Associated with Probiotics
What the sources say
- Partly supportedcites [64] Rao S.S.C. Yu S. Tetangco E.P. Yan Y. Probiotics can cause D-lactic acidosis and brain fogginess: Reply to Quigley et al Clin. Transl. Gastroenterol. 2018 9 e207 10.1038/s41424-018-0077-5 PMC6240559 30449886 sourceExperimental — accuracy not yet measured
The reply states that probiotic species produce different amounts of D-lactate and that D-lactate production may contribute to brain fogginess (main text, points 3 and 7; page unavailable). It does not discuss biogenic amines or recommend targeted biochemical screening during development. It also says the underlying study was not designed to determine which probiotic or its contents was safer (point 5). (LLM, conf=0.88)
- Partly supportedcites [65] Barbieri F. Tofalo R. Suzzi G. Biogenic amine production by lactic acid bacteria: A review Foods 2019 8 17 10.3390/foods8010017 30621071 PMC6351943 sourceExperimental — accuracy not yet measured
The Toxicity section says biogenic amines can cause adverse effects and that the ability to produce them is generally strain-specific. The Conclusions recommend selecting strains that cannot produce them. These passages support the biogenic-amine risk and screening rationale, but our copy does not substantiate the D-lactate example. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The identification of mobile antimicrobial resistance genes and their potential impact on intestinal resistance also requires whole-genome sequencing and detailed characterization of antibiotic resistance genes [42,66,67,68].”
§ Current Concepts in Probiotic Safety and Efficacy > 3. Safety, Toxicity and Other Risks Associated with Probiotics
What the sources say
- Not matchedcites [42] FDA Microorganisms & Microbial-Derived Ingredients Used in Food. FDA, 2018 Available online: https://www.fda.gov/food/generally-recognized-safe-gras/microorganisms-microbial-derived-ingredients-used-food-partial-list (accessed on 22 December 2025)
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [66] Montassier E. Valdés-Mas R. Batard E. Zmora N. Dori-Bachash M. Suez J. Elinav E. Probiotics impact the antibiotic resistance gene reservoir along the human GI tract in a person-specific and antibiotic-dependent manner Nat. Microbiol. 2021 6 1361 1372 10.1038/s41564-021-00920-0 34226711 PMC8318886 sourceExperimental — accuracy not yet measured
The Methods describe shotgun sequencing and detailed ARG and mobile-genetic-element profiling. The Results assess potential horizontal transfer, but the Discussion says further studies are needed to prove transfer and resulting resistance. The paper therefore supports the value of this characterization, not the claim that whole-genome sequencing is required to identify mobile ARGs or establish their impact on intestinal resistance. (LLM, conf=0.83)
- Partly supportedcites [67] Papp M. Solymosi N. Review and comparison of antimicrobial resistance gene databases Antibiotics 2022 11 339 10.3390/antibiotics11030339 35326803 PMC8944830 sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says genome sequencing is commonly used in antimicrobial-resistance surveillance and that tools and databases analyze resistance genes in bacterial genomes and metagenomic samples. It also discusses genes with potential mobilization properties. It does not say whole-genome sequencing is required to identify mobile genes or assess their impact on intestinal resistance; the only intestinal-resistome match is a reference title. (LLM, conf=0.85)
- Partly supportedcites [68] Karnachuk O.V. Beletsky A.V. Rakitin A.L. Ikkert O.P. Avakyan M.R. Zyusman V.S. Mardanov A.V. Ravin N.V. Antibiotic-resistant Desulfovibrio produces H2S from supplements for animal farming Microorganisms 2023 11 838 10.3390/microorganisms11040838 37110261 PMC10146906 sourceExperimental — accuracy not yet measured
Methods §2.2 describes sequencing the L2 genome, and Results §3.3 uses that genome to identify and characterize resistance genes on a plasmid and chromosome. The Discussion §4 links those genes to potential lateral transfer, but the paper does not establish that whole-genome sequencing is required in general or measure an impact on intestinal resistance. Page numbers are unavailable in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
107 more claims · 48 with their cited sources checked
Create a free account to see all 186 claims and to verify the 6 references still open.
- It may state two separate claims as one. 61
- Probably not a substantial claim. 21
Citations
Cites
Hill (2014) · doi:10.1038/nrgastro.2014.66 · Cited by 9,592 · cited 2×
“…experimental and must undergo rigorous external validation and biological confirmation before they can be considered by regulators, highlighting that computational methods complement existing safety assessments based on standardized phenotypic testing and strain-level documentation [151,153,167].”
CARD 2020: Antibiotic Resistome Surveillance with the Comprehensive Antibiotic Resistance Database
Alcock, B. P., Raphenya, A. R., Lau, T. T. Y., Tsang, K. K., Bouchard, M., Edalatmand, A., Huynh, W., Nguyen, A.-L. V., Cheng, A. A., Liu, S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz935 · Cited by 3,202
Mechanisms of Antibiotic Resistance
Munita, J. M., & Arias, C. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.vmbf-0016-2015 · Cited by 2,782
Salminen, S., Collado, M. C., Endo, A., Hill, C., Lebeer, S., Quigley, E. M. M., Sanders, M. E., Shamir, R., Swann, J. R., Szajewska, H., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00440-6 · Cited by 2,488 · cited 3×
“The use of dead cells in postbiotics eliminates the problem of fluctuations in quantitative composition during shelf life and is a good alternative to other groups [25,27].”
Probiotics and prebiotics in intestinal health and disease: from biology to the clinic
Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R., & Rastall, R. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0173-3 · Cited by 2,059 · cited 3×
“…experimental and must undergo rigorous external validation and biological confirmation before they can be considered by regulators, highlighting that computational methods complement existing safety assessments based on standardized phenotypic testing and strain-level documentation [151,153,167].”
Mechanisms of action of probiotics
Plaza-Diaz, J., Ruiz-Ojeda, F. J., Gil-Campos, M., & Gil, A. (2019) · Advances in Nutrition · doi:10.1093/advances/nmy063 · Cited by 1,423
Human gut microbiome: Hopes, threats and promises
Cani, P. D. (2018) · Gut · doi:10.1136/gutjnl-2018-316723 · Cited by 1,386 · cited 1×
“…are crucial for non-traditional probiotic candidates derived from gut commensals that lack a long history of safe use—such as Akkermansia , Faecalibacterium , Bacteroides , and Clostridium species—where in silico analyses complement phenotypic testing to accelerate safe development [153,162].”
Metabolic syndrome: pathophysiology, management, and modulation by natural compounds
Rochlani, Y., Pothineni, N. V., Kovelamudi, S., & Mehta, J. L. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944717711379 · Cited by 1,097 · cited 1×
“…disruption, high blood pressure, liver and kidney dysfunction, as well as excess body weight, abdominal obesity, and/or insulin resistance) [106], which is often associated with an increased risk of cardiovascular diseases and type 2 diabetes [107], and insulin resistance of various…”
Guidance on the characterisation of microorganisms used as feed additives or as production organisms
(FEEDAP), E. P. O. A. A. P. O. S. U. I. A. F., Rychen, G., Aquilina, G., Azimonti, G., Bampidis, V., Bastos, M. D. L., Bories, G., Chesson, A., Cocconcelli, P. S., Flachowsky, G., et al. (2018) · EFSA Journal · doi:10.2903/j.efsa.2018.5206 · Cited by 1,009
Next-generation probiotics: the spectrum from probiotics to live biotherapeutics
O’Toole, P. W., Marchesi, J. R., & Hill, C. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.57 · Cited by 971
Cited by
Probiotic-fortified functional foods: integrating nutrient delivery and gut health benefits
Alsanie, S. A. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1815558 · Cited by 4
“Clinical studies suggest that effective doses generally range between 10 8 and 10 11 CFU/day, though optimal dosing varies by strain and indication (11).”
Carneiro, K. O., Alves, M. V., & Todorov, S. D. (2026) · Antonie van Leeuwenhoek · doi:10.1007/s10482-026-02335-5 · Cited by 3
“( 1234567890) and increased attention can be explained by the numerous interactions with the environment, the development of antimicrobial resistance (antibiotics and biocides), genetic alterations, and mutations (Churin et al. 2026).”
Chong, S. Y., Raja‐Razali, R. B., Ismail, N. H., Ushidee-Radzi, M. A., Zahia-Azizan, N. A., Manickam, M., Norhisham, D. ‘., Ilham, Z., Reale, A., Nazzaro, S., et al. (2026) · Foods · doi:10.3390/foods15122079 · Cited by 2
“The safety evaluation of probiotic LAB frequently involves an examination of hemolytic activity, antibiotic resistance patterns, pathogenic potential, and metabolic by-products [355].”
Purohit, H. V., Chakraborty, J., Kothari, R. K., & Bhatt, A. R. (2026) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-026-11029-3 · Cited by 3
Predicting Host-Interaction Traits in Probiotic Bacteria Using Machine Learning and Functional Data
da Luz, G. D. Q., Kappel, K. S., Dias, R. S., Leite, F. P. L., & Kremer, F. S. (2026) · Journal of Genome Biotechnology and Genetics · doi:10.3390/jgbg1020012 · Cited by 1
“However, genomic analysis based solely on sequence alignments and homology does not capture higher-order interactions among genomic components [8].”
Metadata
- Authors
- Churin, A. A., Sokolyanskaya, L. O., Lukina, A. P., & Karnachuk, O. V.
- Affiliations
- National Research Tomsk State University (RU)
- Corresponding author
- Churin, Alexey A.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2026-02-21
- Volume
- 18
- Issue
- 4
- Pages
- 696
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC12942808
- OpenAlex
- W7130931644
- Cited by
- 31
- References
- 175
- Citations by year
- 2026: 31
- FWCI
- 16.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Russian Science Foundation (25-24-00493)
- Topics
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- probiotics, probiotic safety, probiotic efficacy, adverse events, probiotic regulation, live biotherapeutic products, dietary supplements, safety assessment, microbiome
- MeSH terms
- Humans, Dietary Supplements, Probiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Concepts in Probiotic Safety and Efficacy. https://app.cochat.ai/papers/10.3390/nu18040696
- The paper
- Churin, A. A., Sokolyanskaya, L. O., Lukina, A. P., & Karnachuk, O. V. (2026). Current Concepts in Probiotic Safety and Efficacy. Nutrients. https://doi.org/10.3390/nu18040696
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.